.Attribute Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a mean consequence of 11 months, individuals along with metastatic stomach tumors that received biomarker-matched treatments based upon flowing cyst DNA profiling revealed a more significant professional advantage than those acquiring unrivaled treatment.